Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis

    Hengrui Liang
    Hengrui Liang
    Guo Lin
    Guo Lin
    Yilin Yang
    Yilin Yang
    Yuting Lan
    Yuting Lan
    Runchen Wang
    Runchen Wang
    Zhexue Hao
    Zhexue Hao
    Hongsheng Deng
    Hongsheng Deng
    Shen Zhao
    Shen Zhao
    Bo Cheng
    Bo Cheng

    Translational lung cancer research, pp. 188-203, 2020.

    Cited by: 0|Bibtex|Views1|Links
    WOS
    Keywords:
    PD-1/L1 inhibitorsfront-linenetwork meta-analysis (NMA)non-small cell lung cancer (NSCLC)

    Abstract:

    We conducted a systematic comparison of first line immunotherapy for advanced NSCLC. Chemo-immunotherapies were better than chemotherapy and mono-immunotherapies in most patients. Pembrolizumab might have better efficacy than other PD-1/L1 inhibitors.

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments